GL1X · GenesisL1 explorer

Research workbench

Co-crystal structure of ACK1 with inhibitor

Analyse Co-crystal structure of ACK1 with inhibitor in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
4EWH
Type
protein
Length
549 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Activated CDC42 kinase 1
EC
2.7.10.2, 2.7.11.1
UniProt
Q07912
Ligands
T77
Pockets
5 · best druggability 0.63

Structure

x-ray diffraction · 2 distinct chains · 38% helix, 21% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
BActivated CDC42 kinase 1 (EC 2.7.10.2, 2.7.11.1)protein27438% helix, 22% strandQ07912
AActivated CDC42 kinase 1 (EC 2.7.10.2, 2.7.11.1)protein27538% helix, 21% strandQ07912

Ligands and binding sites

  • T77 · 6-{4-[2-(dimethylamino)ethoxy]phenyl}-N-(1,3-dithiolan-2-ylmethyl)-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine · ligand · 2 copies · chains B, A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13270.630.7941T77
22940.610.7943T77
32610.550.7742empty
42370.530.7726empty
5940.410.7818empty

Interfaces

1 interface between chains.

  • B–A · 829 Ų buried · 9 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 modified (phosphorylation).

Compared structures

  • 4EWH · Co-crystal structure of ACK1 with inhibitor · the same entry in another collection · chain B against B, TM-score 1.00
  • Q07912 · AlphaFold monomer V2.0 prediction for activated CDC42 kinase 1 (Q07912) · a predicted model of the same protein · chain A against A, TM-score 0.95

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.